Very interesting that 25 was picked for Mexico a relatively long time ago.

Surely something would have been adjusted, endpoints, patient numbers, or whatever.

Suggests something besides statistics, like probably cost, was the main driver in Mexico trial design, especially if Mexico can use US trial results to approve.